OverviewChartNewsTraderScreen

HSBC TUR.WAR.OP.END. 4AB/  DE000HS44HR9  /

gettex Zettex2
2024-06-07  9:36:44 PM Chg.-0.0100 Bid9:59:24 PM Ask9:59:24 PM Underlying Strike price Expiration date Option type
0.3700EUR -2.63% 0.3600
Bid Size: 300,000		 0.3700
Ask Size: 300,000		 AbbVie Inc 208.4066 USD 2078-12-31 Put
GlobeNewswire 06-05 CEREVEL INVESTIGATION ALERT: Cerevel (Nasdaq: CERE) Investors are Encouraged to Contact BFA Law abou...
GlobeNewswire 06-05 Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
GlobeNewswire 06-05 OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR...
GlobeNewswire 06-04 Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewswire 06-04 BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID
GlobeNewswire 06-03 Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
GlobeNewswire 06-03 ACQUISITION NEWS: Cerevel’s (Nasdaq: CERE) $45 Merger Offer is Being Investigated for Being Too Low,...
GlobeNewswire 06-01 CERE (NASDAQ) REMINDER: BFA Law Reminds Cerevel Shareholders to Inquire About Ongoing Investigation ...
GlobeNewswire 05-30 OSE Immunotherapeutics Provides Business and Corporate Update
GlobeNewswire 05-29 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach
GlobeNewswire 05-28 Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Imp...
GlobeNewswire 05-28 CEREVEL THERAPEUTICS ALERT: Cerevel’s $45 Merger Offer From AbbVie is Under Investigation (Nasdaq: C...
GlobeNewswire 05-28 Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
GlobeNewswire 05-25 CERE (NASDAQ) ALERT: Cerevel’s $45 Merger Offer From AbbVie is Under Investigation; Contact BFA Law ...
GlobeNewswire 05-24 Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7...
GlobeNewswire 05-23 Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine recept...
GlobeNewswire 05-22 Over 130 Resident Dermatologists Receive In-Depth Cosmetic Training From Renowned ASDS Member Physic...
GlobeNewswire 05-22 Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $57...
GlobeNewswire 05-22 CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
GlobeNewswire 05-22 Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $57...
GlobeNewswire 05-22 Anavex Life Sciences Announces Expansion of Leadership Team
GlobeNewswire 05-22 OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treat...
GlobeNewswire 05-21 COUR Pharmaceuticals Appoints Paul M. Peloso, MD, as Chief Medical Officer
GlobeNewswire 05-21 BREAKING CEREVEL INVESTIGATION: BFA Law Is Investigating the $45 Per CERE (Nasdaq) Share Offer by Ab...
GlobeNewswire 05-21 Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.